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11. CYSTATHIONINE P-SYNTHASE
DEFICIENCY: METABOLIC ASPECTS

s. Harvey Mudd

Introduction
Cystathionine ~-synthase (CBS) deficiency was first
demonstrated in 1964 in an eight-year-old mentally
retarded girl with bilaterally dislocated optic lenses
who excreted abnormally elevated amounts of homocystine in her urine {l]. Patients with similar metabolic abnormalities and clinical findings had first
been discovered 2 years earlier by Carson and her
colleagues during a survey of mentally backward
children in Northern Ireland [2}. CBS deficiency
has proven to be the most frequently encountered of
the human genetic diseases causing homoeystinuria
and severe hyperhomocyst(e)inemia. Worldwide, it is
detected with a frequency of about 1: 344,000 by
screening programs of the newborn, but this is undoubtedly an underestimate because some individuals are being missed [3]. This chapter will briefly
focus on the major clinical manifestations and metabolic aspects of CBS deficiency.

Major Clinical Features
Clinically, the most prominent features of CBS deficiency are mental retardation, dislocation of the optic
lenses, a tendency toward early thromboembolic
events, and osteoporosis and other bony abnormalities. An international survey published in 1985 [4}
presented data on 629 CBS-deficient patients. Among
those so classified, some 44% were judged to be B6responsive; that is, when given high doses of pyridoxine they underwent prompt and marked decreases in
plasma homocyst(e)ine and methionine concentrations. An equal proportion were judged nonresponsive, with little or no decreases in the abnormally
elevated concentrations of these amino acids following pyridoxine administration. Although this crude
classification is undoubtedly an oversimplification,
the results clearly showed that in the absence of specific treatment, as a group the B6-nonresponsive patients were more severely affected clinically than were
the B6-responsive patients. The median IQ for

nonresponders was 56; for responders, 78. Among
untreated patients, optic lens dislocation had occurred in 50% of nonresponders by age six years, a
clinically apparent thromboembolic event had occurred in 25% of patients by age 15 years, and spinal
osteoporosis was detected in 50% by age 12. By contrast, the corresponding ages for untreated B6responders were 10,20, and 20 years.

Metabolic Aspects
The primary abnormality in CBS-deficient patients is
a failure to covert homocysteine to cystathionine, a
process that normally must occur chiefly in the liver.
Mansoor and colleagues [5} have shown that in normal plasma, only 2% of the homocysteine-derived
moieties exist as homocysteine itself; 16% occur as
free disulfides (homocystine, homocysteine-cysteine
mixed disulfide, other mixed disulfides); and 82% are
bound to protein as mixed disulfides of homocysteine
and protein cysteine [5}. Comparable measurements
by modern methods have not been reported for intracellular homocysteine-derived moieties in CBSdeficient patients. Clearly there is some export of
the abnormally accumulated homocysteine so that the
total plasma homocyst(e)ine (tHcy) rises dramatically.
The greatest relative rise occurs in homocysteine, with
lesser rises in free disulfides and the protein-bound
mixed disulfide (up to 400-fold, 90-fold, and 20-fold
above normal, respectively) [6}. Plasma methionine
also rises in most CBS-deficient patients, presumably
due to enhanced methylation of abnormally elevated
homocysteine. The source(s) of the methyl group for
such methylation is (are) uncertain. The availability
of betaine must be limiting under normal dietary
conditions because administration of betaine usually
results in further decreases in tHey. N 5-Methyltetrahydrofolate would be expected to provide an
alternative supply of methyls (see below).
Additional compounds that would be expected to
accumulate abnormally in cells of CBS-deficient pa-
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tients include S-adenosylhomocysteine (AdoHcy) (if
adenosine is available) and S-adenosylmethionine
(AdoMet). The former is expected to accumulate because the equilibrium of AdoHcy hydrolase favors
AdoHcy formation, and the latter because of the elevated methionine concentration in the presence of
intact methionine adenosyltransferase that (in the
liver) is normally operating far below saturation with
respect to that substrate. Neither of these compounds
has been measured in liver or other tissue of CBSdeficient patients by use of methods that are now
known to be necessary to avoid rapid changes after
tissue is removed from the body. Indirect evidence
for an abnormal elevation of AdoHcy is provided
by the fact that Perry and coworkers {7,8) found
unusual amounts of this compound and of 5-amino-4imidazolecarboxamide-5'-S-homocysteinylriboside, a
compound structurally (and presumably metabolically) closely related to AdoHcy, in the urines of their
CBS-deficient patients.
The intracellular AdoMet/AdoHcy ratio, often
termed the "methylation index," will determine
the relative activities of most AdoMet-dependent
methyltransferases (9). It can be inferred that this
ratio may be relatively undisturbed in CBS-deficient
patients by the fact that they seem not to suffer
from the neurologic abnormalities associated with
defective myelination that are common in patients
with methylenetetrahydrofolate reductase (MTHFR)
deficiency {lO) who, because of their low, or low
normal, methionine and elevated tHcy concentrations, may be expected have low AdoMet/AdoHcy
ratios. Jencks and Matthews stated that the physiologic activity of MTHFR "must ... be determined
by competition between AdoMet and AdoHcy for
a common ligand-binding site and would therefore
be expected to be very sensitive to the AdoMet/
AdoHcy ratio" (11). The inferred normality of this
ratio in CBS-deficient patients would mean that there
is no interference with the biosynthetic pathway to
N l -methyltetrahydrofolate, and that there should be
sufficient amounts of this compound to support methylation of the abnormally elevated homocysteine.
The increased input of methyl groups through
homocysteine methylation raises the problem of
how these methyl groups are to be disposed of. If
utilization for homocysteine methylation keeps N l _
methyltetrahydrofolate at a low concentration, glycine methyltransferase will be active and methyl
groups will flow to sarcosine as a step in their
ultimate oxidation. It would thus be of interest to
assess quantitatively the rates of homocysteine
methylation and sarcosine formation in CBS-deficient
patients.

The metabolic consequences of CBS deficiency
might be expected to include abnormally low rates of
synthesis of compounds distal to the enzyme block,
including cystathionine and cysteine. Because a relatively small residual activity of CBS may support a
substantial flux of homocysteine into cystathionine
(see below), the extent of the abnormalities in
cystathionine and cysteine in a given patient will
probably depend upon how much residual CBS activity is present. Cystathionine is present in normal
human brain at high concentrations (12), but was
present at most only in trace amounts in brains
obtained at postmortem examination of three homocystinuric individuals {l3,14). In the absence of data
on the B6-responsiveness of these patients, it is uncertain whether or not they had any residual CBS activity. Reliable assays of tissue cysteine concentrations
have not been reported, but Mansoor et al. (6) found
that in seven patients with homocystinuria and
hypermethioninemia consistent with CBS deficiency
(but not specified with respect to B6-responsiveness),
plasma concentrations of total cyst(e)ine ranged from
52 to 167~, below the mean normal value of approximately 250~ (6).

The Mechanism of B6-responsiveness
As discussed above, a major determinant of the clinical prognosis for CBS-deficient patients is whether or
not they are B6-responsive. In considering possible
mechanisms of response it is important to realize that
although B6 administration may bring about marked
drops in plasma tHcy and methionine in responsive
patients together with rises in abnormally low plasma
cyst(e)ine concentrations, these patients are not restored to biochemical normalcy. They usually continue to have some elevation of homocystine in
plasma and urine, and respond abnormally to a methionine load as judged by the extent and/or duration
of elevations of plasma methionine and of plasma and
urinary homocystine (15,16).
In principle, the B6-induced response could be due
either to stimulation of an alternative pathway for
catabolism of methionine or homocysteine, or to
stimulation of residual CBS activity. No evidence has
been reported indicating stimulation of an alternative
pathway, and indeed there is a possibility that the
methionine transamination pathway, which is the
major known alternative route for methionine degradation, is inhibited in CBS-deficient patients (17).
Furthermore, the genetic evidence now available
proves that B6-responsiveness or nonresponsiveness is
determined by some property of the mutant CBS
itself. This was first indicated by the fact that B6-
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TABLE 11-1. Cystathionine ~-synthase activities in

livers of cysathionine ~-synthase-deficient patients
B6-responsive

B6-nonresponsive
B6 administration

no

yes

no

yes
Citation

Liver CBS activity, % of mean control*

12.3**
30.5**
2.0
1.2
3.7
9.4
5.9
5.6
15.3**
7.1
6.2
4.0

35
36
15

0
3.0
4.6
16.5
11.7
22.6
24.7
55.1
6.7
10.7
8.4

o

0
0

o

37

38

* All in vitro assays with pyridoxal-5'-phosphate added.

** Patient with less marked homocystinuria: genetic status uncertain.

responsiveness or nonresponsiveness is the same for all
CBS-deficient sibs within a given sibship {4}, suggesting that the same (or a closely linked) genetic
mutation that makes an individual CBS-deficient determines whether he will be B6-responsive. More
recent studies of mutations in the CBS gene have
firmly supported this conclusion. Striking examples
include the findings that "the 'Celtic' mutation
G307S appears to be incompatible with B6 responsiveness whether it is present in one or two copies in
the patient" {I8}, and that the prevalent mutation
I278T is associated in homozygotes with B6 responsiveness and, in compound heterozygotes, with some
degree of B6 responsiveness {l9}'
A few assays of CBS activity in livers of CBSdeficient patients were performed before the discovery
that this activity is expressed in normal cultured skin
fibroblasts later obviated the need for studies of liver
for diagnostic purposes. Those carried out with sufficient sensitivity to detect relatively small residual
CBS activities are summarized in table 11-1. Each B6responsive patient had detected residual activity, and
treatment of the patient with therapeutic doses of B6
almost invariably led to at least some increase in the
hepatic activity. Pyridoxal 5'-phosphate was added in
vitro for these assays. This fact, in addition to other
available evidence {3}, makes it clear that in no instance was the deficit in activity overcome merely

by the addition of cofactor, as would be expected
were these simply Km mutations. By contrast, no B6 nonresponsive patient, whether or not given B6, had
detected hepatic activity. *
The physiologic importance of the relatively small
activities of CBS in the B6-responsive patients has
been indicated by measurements of the abilities of
these patients to convert the sulfur of an oral load of
methionine to inorganic sulfate, and by determination by nitrogen balance studies of their capacities to
form cysteine from methionine. The normal human
has the capacity to convert methionine sulfur to inorganic sulfate at a rate of at least 84 millimole/day. In
their basal states, B6-responsive CBS-deficient patients had a mean capacity of 8.3 millimole/day, and
this capacity was increased by B6-treatment to 16.1
millimole/day. Although each of these rates is small
compared to normal, they are sizable compared to the
normal methionine intake of some 8-12 millimole/
day {l5}. Finally, in contrast to normal humans, B6nonresponsive CBS-deficient patients do not maintain

* The results of assays of CBS activities in cultured skin fibroblasts
generally support the suggestion that B6-responsive patients have
small residual activities of CBS, whereas B6-nonresponsive patients
do not {33]. However, experience has shown that such results are
fallible, at least in the sense that individuals who must have CBS
activity in their liver may fail to manifest such activity in cultured
fibroblasts. See, for example, de Franchis et at. {34}.

80

I. BIOCHEMISTRY AND GENETIC STUDIES

nitrogen balance when given methionine-adequate,
cystine-free diets [20,21]. However, B6-responsive
patients, even on normal B6 intakes, did remain in
nitrogen balance on such diets. Titration of the
amount of cystine required to maintain balance in
a nonresponsive patient indicated that the B6responders must be synthesizing each day at least
2.5-4.0 millimole of cysteine, a minimal value that is
sizable compared to the normal methionine intake
[21] and that, if stimulated by no more than two- to
threefold, would become sufficient to metabolize such
an intake.

Are the Vascular-damaging Effects of
Hyperhomocysteinemia Somehow Partially
Mitigated in CBS-deficient Patients and in
Heterozygotes for CBS Deficiency?
The results of long-term treatment of CBS-deficient
patients are now beginning to be reported [22-24].
B6-nontesponsive patients have been free of thromboembolic events, both those in Australia treated
with betaine, B6, folate, and B12 [22,23], and those in
Ireland given low-methionine diets (E Naughten,
personal communication). This is surprising in view
of the fact that, for the Australian patients, medications were given in doses that maintained plasma free
homocyst(e)ine at "usually ... less that 60 J.1M" [22],
so that plasma tHcy may have been at least twice this
value [6]-i.e., at least 120J.1M. Compared with the
levels of hyperhomocyst(e)inemia reported in the abstracts and papers for this meeting to confer significant relative risks of thromboembolic phenomena,
120JlM is extremely high. Why have these patients
been free of thromboembolism?
The same question arises with regard to heterozygotes for CBS deficiency. Such individuals are not
overrepresented among individuals with premature
vascular disease [25,26], and are at little, if any,
increased relative risk for such disease [27,28]. Could
it be that the vascular-damaging effects of hyperhomocyst(e)inemia are somehow mitigated in individuals with partial or severe lack of CBS activiry?
Perhaps methionine acts as a competitive structural
inhibitor of this damage, and the elevated concentrations of this amino acid in CBS-deficient individuals,
in contrast to its normal or low concentrations in
those with homocysteine methylation difficulties, is
protective. Other differences exist between individuals with impaired CBS and impaired homocysteine
methylation-the former have higher concentrations
of AdoMet and lower concentrations of cystathionine
and, perhaps, cysteine; and those with milder impair-

ments are likely to have hyperhomocyst(e)inemia only
following intake of methionine (i.e., at times when
the methionine concentration is also high), rather
than fasting hyperhomocyst(e)inemia [29,30]. Again,
if the transsulfuration pathway is normally not operative in endothelial cells and vascular tissues (a point
upon which present evidence conflicts [31,32]), one
might expect the pathophysiologic effects of a given
extent of hyperhomocyst(e)inemia to be less severe
with impairments of CBS than of homocysteine methylation (JD Finkelstein, personal communication).
These possible mitigating effects are not mutually
exclusive. They may merit being borne in mind as
work progresses on hyperhomocyst(e)inemia and its
role in cardiovascular disease. Perhaps nature's experiments with CBS-deficiency have lessons to teach us
worthy of our attention.
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